anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The group will receive a weekly yoga session for the duration of 10 weeks. The yoga sessions will be delivered in person for 3 weeks during the intervention, coordinated with existing clinic visits. The other 7 sessions will be delivered via skype. The participant will be asked to fill out questionnaires during each of the three in-person yoga visits asking about psychological symptoms and quality of life.
Learn to Quit (LTQ), an evidence-based smoking cessation app tailored to the needs of individuals with serious mental illness (SMI) that demonstrated promising smoking cessation outcomes in a recent pilot randomized controlled trial (R00 DA037276). In parallel, several trials demonstrated that widely available social media platforms can be effectively utilized to enhance the effects of standard of care evidence-based smoking cessation treatments. Both approaches capitalize on highly scalable digital technologies, and are therefore likely to have population level impact. Drawing from these two separate programs of research, the central premise of this proposal is that LTQ, a stand-alone smoking cessation app tailored to patients with SMI, can be enhanced with peer-support delivered on social media. Therefore, this proposal seeks to develop and asses the acceptability and feasibility of LTQ-Connect -- the integration of the evidence-based smoking cessation app, LTQ, with social support delivered via social media -- to boost the efficacy and community reach of digital therapeutics tailored for patients with SMI. To achieve this goal, we will:

(1) determine the ideal design requirements of an LTQ-Connect integration among smokers with SMI, and (2) investigate the feasibility of LTQ-Connect in a single group pilot trial. Both interventions will be combined with nicotine replacement therapy, a safe and widely available medication.
The participants will receive an IV ondansetron infusion with D5W as placebo. Participants will receive either 8mg or 16 mg of iv ondansetron.
Patients undergo 3D surface scans on study. Patient's medical records are also reviewed on study.
All study subjects will receive glecaprevir/pibrentasvir (Mavyret®) 300/120 mg orally x 14 days, starting on POD 0 prior to transplantation of the HCV positive kidney. If HCV RNA is detectable after 2 weeks of therapy, Mavyret® will be continued to complete a full course of 8 weeks per standard of care. Safety monitoring and frequent surveillance for HCV viremia will occur for all subjects throughout the duration of the study. The kidney transplantation procedure and routine post-transplant management will be performed per standard of care.
* The exact way that many drugs work is not well understood. Although how cilostazol works is not completely clear, its main effects are to dilate (widen) the arteries supplying blood to the legs and to decrease the ability of platelets in the blood to stick together. Platelets are particles that circulate in the blood and play a role in clotting
  * Cilostazol may reduce the leg pain that patients with intermittent claudication experience, allowing them to walk farther before their leg pain occurs. 
  * Improvement in symptoms may occur as soon as 2 weeks, but could take up to 12 weeks. If you have not noticed any benefit from cilostazol after 12 weeks you and your doctor may wish to discuss other forms of treatment. 
  * Sometimes blood vessel disease of the legs causes pain at rest or breakdown of skin in the leg. Cilostazol has not been shown to work in patients with these problems.
Under ultrasound guidance, the probe was transversely placed at the lateral level of the umbilicus . Using the in-plane technique, the needle was advanced until the posterior aspect of the rectus muscle was penetrated. No blood and no gas were drawn back; furthermore, a small volume of saline was initially injected to ensure that the needle tip was correctly positioned. When the needle was located between the posterior rectus muscle and posterior sheath, 5ml of 0.25% ropivacaine was injected bilaterally.
The invention discloses a nerve transplanting scheme recommendation method and system based on big data. And acquiring the structure of the nerve graft by adopting an image of the nerve graft in the culture process. A three-dimensional image was constructed by summing the images by 3 sheets. The three-dimensional image acquires more changes in nerve bundles at a time point than the two-dimensional image, and acquires more training data for detecting nerve classes. The neural student model is trained by using a small part of marked data through the teacher student model, and using a large part of unmarked data in an unsupervised mode. The neural student model is based on two modified time convolution networks, acquires the characteristics of the neural student model by using three-dimensional images, and jointly judges the neural category by using the relation between the images and the change relation between the characteristics. The technical effect of accurately selecting the method of the nerve transplanting scheme is achieved.
Nasopharyngeal carcinoma (NPC) is most commonly seen in Southeast Asia, especially in southern and southeastern China, where the incidence rate has been documented between 10 and 150 cases per 100,000 population per year. For advanced or metastatic NPC, chemotherapy remain the mainstay of treatment. The 130-nm albumin-bound formulation of paclitaxel (\[Abraxane, ABX \];Celgene,Summit,NJ) is a promising new agent with more efficient entry to the tumor microenvironment via caveolae-mediated transcytosis and preferential uptake by cancer cells. Superior activity of ABX-based regimens without the necessity for antianaphylactic pretreatments been shown in various solid tumors compared with the traditional solvent-based paclitaxel-based ones. However, the safety and efficacy of combination of ABX and cisplatin (DDP) has not been determined in patients with advanced NPC. In this single center, non-randomized phase IIa study, investigators seek to determine the maximum tolerated dose (MTD) and dose limiting toxicity (DLT) of ABX-DDP, and perform an exploratory study of its efficacy as measured by tumor response.
Compositions and methods for NK cell-based therapy are presented, and NK cells that specifically express and retain IL-2 within cells, wherein the NK cells are stimulated with a chimeric protein having a cancer cell targeting moiety and an IL-12 moiety. Beneficially, such chimeric proteins substantially reduce systemic toxicity and induce IFN- γ secretion in a targeted manner. In addition, chimeric proteins contemplated herein also significantly increase IFN- γ secretion in NK cells expressing and retaining IL-2 within the cell, as compared to native NK cells. Preferred chimeric proteins comprise SEQ ID NO. 1 or SEQ ID NO. 2, and SEQ ID NO. 3.
Hippocampal-sparing whole brain radiotherapy is performed using modern intensity-modulated radiotherapy (IMRT) technique to avoid conformally the hippocampal neural stem-cell structure during WBRT. Prescription dose is 37.5 Gy in 15 fractions.
The experimental group underwent intraoperative measurements (A: short distance from the center of the pancreatic duct to the edge of the pancreas) and (B: pancreatic thickness). When the ratio of the thickness of the short distance from the center of the pancreatic duct to the edge of the pancreas at the pancreatic section was ≥0.401, it was divided into the N1 group (central pancreatic duct). If the ratio was \<0.401, it was divided into the N2 group (eccentric pancreatic duct). The "central pancreatic duct" group was given "1+1 mode" pancreaticojejunostomy; the "eccentric pancreatic duct" group was given "1+1² mode" pancreaticojejunostomy.
PROBLEM TO BE SOLVED: To obtain the subject suppressant useful as curing and preventing agents of diseases associated with crisis caused by adhesion of leucocytes to vascular endothelial cells by containing a compound containing a specific glucuronic acid derivative and a glucosamine derivative in its structure. SOLUTION: This suppressant for adhesion of leucocytes to vascular endothelial cells contains a compound having a glucuronic acid derivative and a glucosamine derivative expressed by formula I  R1 is a protective group, OR10 [R10 is H, a protective group, formula II (R13 is an azide or the likes: and R12, R14 and R15 are each H, a protective group) or the likes], NHR11 (R11 is H or a protective group), CH2R11 or SR11, R2 to R8 are each H or a protective group; R9 is H, a protective group formula III (R31 to R34 are each H or a protective group) or the likes, and (n) is 0-25}, (e.g. a compound expressed by formula IV) in its structure. The compound of formula I is obtained by a method, etc. for synthesizing and modifying an intermediate or the objective compound by an organic chemical means using a glucuronic acid derivative, a glucosamine derivative or the likes as a raw material.  The dose is 0.01-100 mg/kg/day for adult in oral administration and 0.001-10 mg/kg/day for adult in parenteral administration.
Generally, when estrogen therapy is prescribed for a postmenopausal woman with a uterus, a progestin should be considered to reduce the risk of endometrial cancer [see Boxed Warning].

A woman without a uterus does not need progestin. In some cases, however, hysterectomized women with a history of endometriosis may need a progestin [see Warnings and Precautions (5.2, 5.16)]. 

Use of estrogen-alone, or in combination with a progestin, should be with the lowest effective dose and for the shortest duration consistent with treatment goals and risks for the individual woman. Postmenopausal women should be re-evaluated periodically as clinically appropriate to determine if treatment is still necessary. 

PREMARIN may be taken without regard to meals.
In patients treated with GLP-1 receptor agonists, including SAXENDA, there have been reports of acute renal failure and worsening of chronic renal failure, sometimes requiring hemodialysis [see Adverse Reactions (6.2)]. Some of these events were reported in patients without known underlying renal disease. A majority of the reported events occurred in patients who had experienced nausea, vomiting, or diarrhea leading to volume depletion. Some of the reported events occurred in patients receiving one or more medications known to affect renal function or volume status. Altered renal function has been reversed in many of the reported cases with supportive treatment and discontinuation of potentially causative agents, including liraglutide. Use caution when initiating or escalating doses of SAXENDA in patients with renal impairment [see Use in Specific Populations (8.6)].
According to the invention, a method is proposed for the qualitative evaluation of real-time PCR data, wherein a time/PCR amplification plot of an associated sample is classified as a negative plot or as a positive plot. A real-time PCR amplification plot to be classified plotting at least 20 successive amplitude values of corresponding successive PCR cycle indices of an associated sample is provided. Furthermore, a quality metric is determined, preferably an individual quality metric which indicates a similarity of the real-time PCR amplification plot to be classified to a straight line, on the basis of the at least one amplitude value. In a further step, a first criterion is determined by means of a comparison of the quality metric with a first standard value. In a further step, a sequence of values is determined which indicates a gradient of the PCR amplification plot to be classified, and a second criterion as to whether the sequence of values exceeds a second standard value is determined. Finally, the real-time PCR amplification plot is classified as a positive plot in the event that all the criteria given above are satisfied.
The music therapy songwriting is a method frequently employed in music therapy sessions. This method involves the collaborative creation of lyrics and/or music with the participants. The intervention will consist of nine sessions, each of which will last approximately 30 to 45 minutes. Three sessions will be conducted per week until a minimum of six and a maximum of nine sessions are achieved.
Enzymes from the group consisting of delta-2-desaturases catalyze an important step for the synthesis of multiple unsaturated fatty acids, which are essential to humans and which, for all eukaryotes, serve as important structural elements of the cell membrane and control many vital processes in the organism. This concerns essential nutrients, the need for which having to be covered mainly from plant and animal sources. Known organisms, in which a delta-12-desaturase enzyme naturally occurs, originate exclusively from warm regions, therefore the production of fatty acids requires a supply of heat that is financially expensive and involves the use of extensive equipment. However, organisms also exist that have enzymes that are adapted to the cold. The invention thus relates to a nucleic acid sequence, which codes for enzyme delta-12-desaturase, originates from the marine diatom    Fragilariopsis cylindrus     that is adapted to the cold, and which is formed according to SEQ ID No.1 or as a functional variant or as a segment having at least 8 nucleotides thereof. This results in the provision of a gene that codes for an enzyme, which has properties adapted to the cold and which is important for producing fatty acids, thereby enabling a particularly economical production of fatty acids.
A point of care device for supporting management of medication at a point of care location is provided, comprising: a container defining an interior space accessible via an opening and a sensor system. A sensor system coupled to the container includes one or more vibration sensors, a memory, and a power supply. The vibration sensors (i) detect vibrations or movements resulting from end-user interactions with the container and (ii) output vibration signal data indicative of the vibrations detected. The memory stores the vibration signal data over a defined time period. In a first point of care mode, the container receives and contains used medication delivery devices into the interior space, and to contain said used medication delivery devices therein. In a second processing mode, the container allows access to the interior space for removal of the used medication delivery devices.
PROBLEM TO BE SOLVED: To obtain an aerosol product for hair, comprising an aerosol composition containing an effective liquid and a propellant, inhibiting gloss on the hair, and capable of beautifully showing the hair without being affected by the intensity of light, etc., and without deteriorating the color tone and three- dimensional appearance. SOLUTION: This aerosol product for hair comprises an aerosol composition containing an effective liquid and a propellant. Therein, particles (for example, silica or alumina) in an amount of 10-80 wt.% are contained in a hair-adhering solid content in the aerosol composition. It is preferable that the aerosol composition contains the hair-adhering solid content in an amount of 0.1-20 wt.%. The primary particles of the particles have an average particle diameter of 1-100 nm and a specific surface area of 100-800 m2/g. A resin used for adhering the particles to the hair includes polyvinyl pyrrolidone, and a neutralizing agent for the resin includes 2-amino-methyl-1,3-propanediol.
This study is being done to see if placing babies on the stomach or the back during delayed cord clamping after birth will improve the outcomes of preterm babies. Studies have shown that in some instances, positioning on the belly may help newborns clear their respiratory secretions. Research has shown that preterm babies can have improved breathing and require less support when placed on the stomach (prone position) rather than the back (supine position). Currently there are no guidelines for the best position for neonates to be in while receiving delayed cord clamping. The investigators are hoping to complete a research study to determine if placing preterm babies on their stomachs during the time of delayed cord clamping will improve the breathing of preterm babies and reduce the need for additional oxygen support with a breathing tube (endotracheal intubation). Depending on the outcomes of the study, the investigators are hoping to determine which position results in better outcomes for babies in both the delivery room and in the neonatal intensive care unit. If the investigators are able to determine the optimal position in this study, the investigators hope to improve the outcomes for future babies that are born preterm by placing the baby in the optimal position during delayed cord clamping.
Atomoxetine titrated up to 120 mg/day by week 8 and continues at 120 mg/day through week 24. Diet support group, group counseling and exercise.
Pulmonary arterial hypertension (PAH) is a devastating and progressive disease with limited treatment options. Endothelial dysfunction plays a central role in the development and progression of PAH, yet the underlying mechanisms are incompletely understood. The endosome-lysosome system is important to maintain cellular health, and the small GTPase RAB7 regulates many functions of this system. Here, we explored the role of RAB7 in endothelial cell (EC) function and lung vascular homeostasis. We found reduced expression of RAB7 in ECs from patients with PAH. Endothelial haploinsufficiency of RAB7 caused spontaneous pulmonary hypertension (PH) in mice. Silencing of RAB7 in ECs induced broad changes in gene expression revealed via RNA-Seq, and RAB7-silenced ECs showed impaired angiogenesis and expansion of a senescent cell fraction, combined with impaired endolysosomal trafficking and degradation, suggesting inhibition of autophagy at the predegradation level. Furthermore, mitochondrial membrane potential and oxidative phosphorylation were decreased, and glycolysis was enhanced. Treatment with the RAB7 activator ML-098 reduced established PH in rats with chronic hypoxia/SU5416. In conclusion, we demonstrate for the first time to our knowledge the fundamental impairment of EC function by loss of RAB7, causing PH, and show RAB7 activation to be a potential therapeutic strategy in a preclinical model of PH.
Users randomized to arm 1 will receive standard monthly recruitment push messages. These push messages will differ from the certification messages because they will contain language intended to foster engagement with OEND services (eg, to get trained and carry naloxone) alongside the link to a landing page.
Cardiac Electrophysiology

In a multicenter, randomized, double-blind trial using tiotropium dry powder for inhalation that enrolled 198 patients with COPD, the number of subjects with changes from baseline-corrected QT interval of 30 to 60 msec was higher in the SPIRIVA group as compared with placebo. This difference was apparent using both the Bazett (QTcB) [20 (20%) patients vs. 12 (12%) patients] and Fredericia (QTcF) [16 (16%) patients vs. 1 (1%) patient] corrections of QT for heart rate. No patients in either group had either QTcB or QTcF of >500 msec. Other clinical trials with SPIRIVA did not detect an effect of the drug on QTc intervals.

The effect of tiotropium dry powder for inhalation on QT interval was also evaluated in a randomized, placebo- and positive-controlled crossover study in 53 healthy volunteers. Subjects received tiotropium inhalation powder 18 mcg, 54 mcg (3 times the recommended dose), or placebo for 12 days. ECG assessments were performed at baseline and throughout the dosing interval following the first and last dose of study medication. Relative to placebo, the maximum mean change from baseline in study-specific QTc interval was 3.2 msec and 0.8 msec for tiotropium inhalation powder 18 mcg and 54 mcg, respectively. No subject showed a new onset of QTc >500 msec or QTc changes from baseline of ≥60 msec.
PURPOSE: To evaluate measurement properties of the Impact of Weight on Quality of Life-Lite (IWQOL-Lite) instrument among Chinese overweight and obese populations.
METHODS: A representative sample of Chinese overweight and obese populations was recruited stratified by age, sex, residence and body mass index (BMI). Social-demographic characteristics, self-reported EQ-5D-5 L and IWQOL-Lite responses were collected through the online survey. Test-retest reliability was assessed using intraclass correlation coefficient (ICC) among a subgroup of the total sample. Structural validity was evaluated by confirmatory factor analysis (CFA). Convergent validity and known-group validity were examined using Spearman's rank correlation and effect sizes, respectively.
RESULTS: A total of 1000 respondents (48% female; mean age: 51.7 years; mean BMI: 27.4) were included in this study. Ceiling and floor effects of the IWQOL-Lite were 5.4% and 0.67%, respectively. The ICC between the two tests was 0.992 for IWQOL-Lite among the subgroup (N = 150). The results of the CFA suggested that the five-factor model had an acceptable structural validity (GFI = 0.894, CFI = 0.960, TLI = 0.957, RMSEA = 0.054 and SRMR = 0.033). The Spearman's rank correlation (range: 0.413-0.611) indicated a satisfactory convergent validity. The effect sizes values of IWQOL-Lite total score and different dimensions were moderate.
CONCLUSIONS: The IWQOL-Lite has been demonstrated to have satisfactory validity and reliability in measuring the HRQoL of Chinese overweight and obese populations. Further research is needed to confirm the sensitivity and responsiveness.
PURPOSE:To obtain an agent effective in actively and directly promoting the cure of the operation scar of surgical operation by using epidermal growth factor(EGF) as an active component. CONSTITUTION:The active component of the subject agent is a beta-urogastrone having an amino acid sequence of formula (dotted line is disulfide bond), gamma- urogastrone having a structure produced by depleting one amino acid from the C-terminal of beta-urogastrone, a compound having a structure produced by depleting 2-7 amino acids from the beta-urogastrone, etc. The daily dose of EGF is preferably about 0.01-100mug/kg for injection. High cure-promoting effect can be expected when the operation site is an organ or tissue having EGF receptor (e.g. digestive organs, kidney and skin). EGF can be produced e.g. by the purification of human urine extract, the gene recombination technique, etc.
Each subject may elect to participate in up to five (5) study scans per day lasting up to 60 cumulative minutes each with approximately a 15 minute break before starting another study scan. Ophthalmic scanning will be limited to no more than 15 cumulative minutes of scan time per eye, per day.
This clinical trial is a single-arm study in which asymptomatic 45-year-old women undergo a triple screening test: (1) two-view tomosynthesis of both breasts; (2) calculation of volumetric breast density (VBD); (3) assessment of breast cancer risk using the Tyrer-Cuzick model. Mean VBD and lifetime risk (LTR) are used to determine the type of imaging and frequency of subsequent screening cycles.
Arm where participants began the intervention (the Spirituality Teaching Program) after an 8 week wait period. Therefore, the program was initiated at week 8 of the trial. Between week 1 and week 8, participants did not complete the program and were instructed to carry out their day to day activities as before.